本計畫於民國八十四年度(83年9月至84年3月),由北、高兩市及全省各縣市抽購國產及進口二種頭孢子菌素類(Cephalosporin)抗生素製劑:賜福力欣(Cephalexin)及西華車西(Cefadroxil)之膠囊製劑共100件。其中賜福力欣膠囊67件,國產66件涵蓋23家廠牌,進口1件;西華卓西膠囊33件,國產32件涵蓋10家廠牌,進口1件。依據日本抗生物質醫藥品基準解說1993年版(Minimum Requirements for Antibiotic Products of Japan,MRAP 1993)所載之高效液相層析法(High Performance Liquid Chromatography)測定其力價,結果顯示賜福力欣及西華卓西膠囊均符合藥典規定(90-120%),合格率為100%。
In an attempt to determine the quality of cephalosporin antibiotic capsules after the implementation of GMP, a total of 100 samples were purchased from Taiwan area in 1994. Among these samples 98 represented domestic products manufactured by 33 drug companies and the remaining 2 were imported and distributed by 2 comp-nies. 67 out of 100 samples were cephalexin while the remaining were cefadroxil. A high performance liquid chromatography (HPLC) method in MRAP 1993 was employed to test these samples. The results showed that all the samples met the potency requirement (90-120%).